Quick Answer
MAXCYTE, INC. reported Gross Profit of $26.80 million for the year ending 2025.
- MAXCYTE, INC. showed a decrease of -15.0% in Gross Profit from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $4.68 million | Q3 2020: $6.03 million | Q1 2021: $5.80 million | Q2 2021: $6.32 million | Q3 2021: $9.20 million | Q1 2022: $10.52 million | Q2 2022: $8.49 million | Q3 2022: $9.27 million | Q1 2023: $7.58 million | Q2 2023: $7.67 million | Q3 2023: $7.21 million | Q1 2024: $9.94 million | Q2 2024: $8.94 million | Q3 2024: $6.24 million | Q1 2025: $8.89 million | Q2 2025: $6.99 million | Q3 2025: $5.23 million.
- Over the full 7 years of available data (2019 to 2025), MAXCYTE, INC.'s Gross Profit has grown by 40.2%.
- Historical annual values: Fiscal year 2025: $26.80 million | Fiscal year 2024: $31.53 million | Fiscal year 2023: $36.55 million | Fiscal year 2022: $39.16 million | Fiscal year 2021: $30.25 million | Fiscal year 2020: $23.40 million | Fiscal year 2019: $19.12 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: